[go: up one dir, main page]

MA28583B1 - Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale - Google Patents

Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale

Info

Publication number
MA28583B1
MA28583B1 MA29452A MA29452A MA28583B1 MA 28583 B1 MA28583 B1 MA 28583B1 MA 29452 A MA29452 A MA 29452A MA 29452 A MA29452 A MA 29452A MA 28583 B1 MA28583 B1 MA 28583B1
Authority
MA
Morocco
Prior art keywords
treatment
cell growth
abnormal cell
pyrimidine derivatives
pyrimidine
Prior art date
Application number
MA29452A
Other languages
English (en)
French (fr)
Inventor
Michael Joseph Luzzio
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28583(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA28583B1 publication Critical patent/MA28583B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA29452A 2004-05-14 2006-11-14 Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale MA28583B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
MA28583B1 true MA28583B1 (fr) 2007-05-02

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29452A MA28583B1 (fr) 2004-05-14 2006-11-14 Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale

Country Status (27)

Country Link
EP (1) EP1751143A1 (es)
JP (1) JP4099212B2 (es)
KR (1) KR100886990B1 (es)
CN (2) CN1953974A (es)
AP (1) AP2241A (es)
AR (1) AR049097A1 (es)
AU (2) AU2005243397A1 (es)
BR (1) BRPI0511138A (es)
CA (1) CA2566707A1 (es)
CR (1) CR8749A (es)
EA (1) EA200601796A1 (es)
EC (1) ECSP066997A (es)
GE (1) GEP20104875B (es)
GT (1) GT200500113A (es)
IL (1) IL178828A0 (es)
MA (1) MA28583B1 (es)
MX (1) MXPA06011890A (es)
NL (2) NL1029045C2 (es)
NO (1) NO20064576L (es)
NZ (1) NZ550448A (es)
PA (1) PA8632601A1 (es)
PE (1) PE20060240A1 (es)
TN (1) TNSN06370A1 (es)
TW (1) TWI303635B (es)
UY (1) UY28894A1 (es)
WO (1) WO2005111023A1 (es)
ZA (1) ZA200608394B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118544A2 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EA014551B1 (ru) * 2005-12-21 2010-12-30 Пфайзер Продактс Инк. Пиримидиновые производные для лечения аномального клеточного роста
UA97834C2 (ru) * 2007-04-18 2012-03-26 Пфайзер Продактс Инк. Производные сульфониламида для лечения анормального роста клеток
WO2009012421A1 (en) * 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
JP2011505407A (ja) * 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン
BRPI0908637B8 (pt) * 2008-05-21 2021-05-25 Ariad Pharma Inc composto e composição farmacêutica do mesmo
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
JP5539518B2 (ja) 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 2−アミノ−5−トリフルオロメチルピリミジン誘導体の位置選択的調製
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2014174745A1 (ja) * 2013-04-26 2014-10-30 国立大学法人京都大学 Eg5阻害剤
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途
WO2024140671A1 (zh) * 2022-12-29 2024-07-04 南京昕瑞再生医药科技有限公司 一种稠三环类衍生物、包含其的药物组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DK1625121T3 (da) * 2002-12-20 2010-05-10 Pfizer Prod Inc Pyrimidinderivater til behandling af abnorm cellevækst

Also Published As

Publication number Publication date
ZA200608394B (en) 2008-05-28
NO20064576L (no) 2006-11-07
JP4099212B2 (ja) 2008-06-11
NL1029045A1 (nl) 2005-11-15
NZ550448A (en) 2010-11-26
EA200601796A1 (ru) 2007-04-27
IL178828A0 (en) 2007-03-08
CN1953974A (zh) 2007-04-25
TW200539871A (en) 2005-12-16
AU2005243397A1 (en) 2005-11-24
BRPI0511138A (pt) 2007-11-27
MXPA06011890A (es) 2006-12-14
TWI303635B (en) 2008-12-01
TNSN06370A1 (fr) 2008-02-22
NL1031845A1 (nl) 2006-07-31
NL1031845C2 (nl) 2006-11-23
AP2006003790A0 (en) 2006-10-31
WO2005111023A1 (en) 2005-11-24
KR20070012477A (ko) 2007-01-25
CA2566707A1 (en) 2005-11-24
PE20060240A1 (es) 2006-04-01
NL1029045C2 (nl) 2006-06-02
EP1751143A1 (en) 2007-02-14
PA8632601A1 (es) 2006-06-02
GEP20104875B (en) 2010-01-11
CR8749A (es) 2006-12-05
UY28894A1 (es) 2005-12-30
KR100886990B1 (ko) 2009-03-04
CN102127058A (zh) 2011-07-20
JP2007537234A (ja) 2007-12-20
ECSP066997A (es) 2007-02-28
GT200500113A (es) 2006-01-10
AR049097A1 (es) 2006-06-28
AU2009238255A1 (en) 2009-12-03
AP2241A (en) 2011-06-01

Similar Documents

Publication Publication Date Title
EP1831385A4 (en) ENZYME FOR STRENGTH PROCESSING
MA28583B1 (fr) Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale
NL1025067A1 (nl) Pyrimidinederivaten voor de behandeling van abnormale celgroei.
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
NO20054404L (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
EP1807396A4 (en) 2-AMINOPYRIDINE COMPOSITIONS AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF MORBUS ALZHEIMER
EP1893224A4 (en) USE OF A PLANT CELL MEMBRANE FOR THE TREATMENT OF ADIPOSITAS
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
EP1581243A4 (en) ORAL LACTOFERRIN FOR SEPSIS TREATMENT
EP1817311A4 (en) 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS AS BETA SEKTRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
FR2871365B1 (fr) Implant pour le traitement de la rectocele ou de la cystocele
EP1750513A4 (en) USE OF GPCR54 LIGANDS FOR THE TREATMENT OF BARRENESS
FR2835851B1 (fr) Composition pour le traitement d'alliages de magnesium
EP1572129A4 (en) AMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOIDOSE
FR2868312B1 (fr) Patch pour le traitement des levres
EP2229172A4 (en) TRIAZOLO [4,5-D] PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF BAUCHAORTANEURYSMS
FR2869622B1 (fr) Comprimes de micro-organismes pour ensemencement direct
PL1687006T3 (pl) Kompozycje farmaceutyczne do leczenia zaburzeń czynności nerek
PT1590046T (pt) Composição para o tratamento de hiv ou sida
FR2887456B1 (fr) "composition pour le traitement de la dermite estivale"
EP1828141A4 (en) STAINING METHOD FOR PREPARING THE ANTIEMETIC 1,2,3,9-TETRAHYDRO-9-METHYL-3 - [(2-METHYL) -1H-IMIDAZOLE-1-YL) METHYL] -4H-CARBAZOLE-4-ON
FR2851247B1 (fr) Methodes et compositions pour le traitement de pathologies degeneratives oculaires
MA28513B1 (fr) Processus pour la preparation d'inhibiteurs de tryptase
FR2877028B1 (fr) Procede d'amenagement de combles